ID

22023

Description

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00374296

Link

https://clinicaltrials.gov/show/NCT00374296

Keywords

Versions (1)
  1. 5/15/17 5/15/17 -
Uploaded on

May 15, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Myelogenous Leukemia, Acute NCT00374296

English

Eligibility Myelogenous Leukemia, Acute NCT00374296

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
pathologic confirmation of aml or high risk mds.
Description

Leukemia, Myelocytic, Acute | MYELODYSPLASTIC SYNDROME High risk

Data type

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2,1]
C3463824
UMLS CUI [2,2]
C0332167
elderly cohort (70 years of age or more): no prior chemotherapy treatment for aml/high risk mds and not currently candidates for intensive chemotherapy.
Description

Cohort Elderly | Age | Chemotherapy Acute Myelocytic Leukemia | Chemotherapy MYELODYSPLASTIC SYNDROME High risk | Chemotherapy With intensity

Data type

boolean

Alias
UMLS CUI [1,1]
C0599755
UMLS CUI [1,2]
C0001792
UMLS CUI [2]
C0001779
UMLS CUI [3,1]
C0392920
UMLS CUI [3,2]
C0023467
UMLS CUI [4,1]
C0392920
UMLS CUI [4,2]
C3463824
UMLS CUI [4,3]
C0332167
UMLS CUI [5,1]
C0392920
UMLS CUI [5,2]
C0522510
relapsed/refractory cohort (18 years of age or more): relapsed or refractory to prior treatment.
Description

Cohort Relapse Refractory | Age | Relapse | Refractory

Data type

boolean

Alias
UMLS CUI [1,1]
C0599755
UMLS CUI [1,2]
C0035020
UMLS CUI [1,3]
C0205269
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0035020
UMLS CUI [4]
C0205269
ecog performance status of 0 or 1.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
total bilirubin < 1.5 x upper limit of normal (uln).
Description

Serum total bilirubin measurement

Data type

boolean

Alias
UMLS CUI [1]
C1278039
ast/sgot and alt/sgpt < 2.5 x uln.
Description

Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201899
UMLS CUI [2]
C0201836
serum creatinine < 1.5 x uln.
Description

Creatinine measurement, serum

Data type

boolean

Alias
UMLS CUI [1]
C0201976
patients must read, understand, and sign a written informed consent form (icf).
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
women of childbearing potential and male patients' female partners must use an acceptable method of contraception while on study, and for 3 months after study drug treatment.
Description

Childbearing Potential Contraceptive methods | Gender Partner Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0682323
UMLS CUI [2,3]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnant or lactating women.
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
patients with uncontrolled, intercurrent illness, active or uncontrolled infections, or a fever > 38.5c (not due to tumor fever) on the day of scheduled dosing.
Description

Comorbidity Uncontrolled | Communicable Diseases | Communicable Diseases Uncontrolled | Fever | Tumour associated fever

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0009450
UMLS CUI [3,1]
C0009450
UMLS CUI [3,2]
C0205318
UMLS CUI [4]
C0015967
UMLS CUI [5]
C0948348
patients with serious illnesses or medical conditions, including laboratory results, which, in the investigator's opinion, would interfere with a patient's participation, or with the interpretation of the results.
Description

Illness Serious Interferes with Study Subject Participation Status | Illness Serious Interferes with research results | Medical condition Serious Interferes with Study Subject Participation Status | Medical condition Serious Interferes with research results | Laboratory Results Interfere with Study Subject Participation Status | Laboratory Results Interfere with research results

Data type

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C2348568
UMLS CUI [2,1]
C0221423
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C0521102
UMLS CUI [2,4]
C0683954
UMLS CUI [3,1]
C3843040
UMLS CUI [3,2]
C0205404
UMLS CUI [3,3]
C0521102
UMLS CUI [3,4]
C2348568
UMLS CUI [4,1]
C3843040
UMLS CUI [4,2]
C0205404
UMLS CUI [4,3]
C0521102
UMLS CUI [4,4]
C0683954
UMLS CUI [5,1]
C1254595
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C2348568
UMLS CUI [6,1]
C1254595
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C0683954
patients treated with an investigational drug within 30 days prior to study initiation.
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
known hypersensitivity to hdac inhibitors or to any of the components of mg-0103.
Description

Hypersensitivity Histone deacetylase inhibitor | Hypersensitivity MG 0103 Component

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1512474
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1831851
UMLS CUI [2,3]
C1705248
known hiv or active hepatitis b or c.
Description

HIV Infection | Hepatitis B | Hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196
any condition that may affect the patient's ability to sign the icf and undergo study procedures.
Description

Condition Affecting Informed Consent | Condition Affecting Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0021430
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C0525058
any conditions that will put the patient at undue risk or discomfort as a result of adherence to study procedures.
Description

Condition Resulting in Patient Risk | Condition Resulting in Patient Discomfort | Protocol Compliance Consequence of

Data type

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0332294
UMLS CUI [1,3]
C0030705
UMLS CUI [1,4]
C0035647
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C0332294
UMLS CUI [2,3]
C0030705
UMLS CUI [2,4]
C2364135
UMLS CUI [3,1]
C0525058
UMLS CUI [3,2]
C0686907
Back to the top of the page

Similar models

Eligibility Myelogenous Leukemia, Acute NCT00374296

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Leukemia, Myelocytic, Acute | MYELODYSPLASTIC SYNDROME High risk
Item
pathologic confirmation of aml or high risk mds.
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2,1])
C0332167 (UMLS CUI [2,2])
Cohort Elderly | Age | Chemotherapy Acute Myelocytic Leukemia | Chemotherapy MYELODYSPLASTIC SYNDROME High risk | Chemotherapy With intensity
Item
elderly cohort (70 years of age or more): no prior chemotherapy treatment for aml/high risk mds and not currently candidates for intensive chemotherapy.
boolean
C0599755 (UMLS CUI [1,1])
C0001792 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
C0392920 (UMLS CUI [3,1])
C0023467 (UMLS CUI [3,2])
C0392920 (UMLS CUI [4,1])
C3463824 (UMLS CUI [4,2])
C0332167 (UMLS CUI [4,3])
C0392920 (UMLS CUI [5,1])
C0522510 (UMLS CUI [5,2])
Cohort Relapse Refractory | Age | Relapse | Refractory
Item
relapsed/refractory cohort (18 years of age or more): relapsed or refractory to prior treatment.
boolean
C0599755 (UMLS CUI [1,1])
C0035020 (UMLS CUI [1,2])
C0205269 (UMLS CUI [1,3])
C0001779 (UMLS CUI [2])
C0035020 (UMLS CUI [3])
C0205269 (UMLS CUI [4])
ECOG performance status
Item
ecog performance status of 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Serum total bilirubin measurement
Item
total bilirubin < 1.5 x upper limit of normal (uln).
boolean
C1278039 (UMLS CUI [1])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
ast/sgot and alt/sgpt < 2.5 x uln.
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
Creatinine measurement, serum
Item
serum creatinine < 1.5 x uln.
boolean
C0201976 (UMLS CUI [1])
Informed Consent
Item
patients must read, understand, and sign a written informed consent form (icf).
boolean
C0021430 (UMLS CUI [1])
Childbearing Potential Contraceptive methods | Gender Partner Contraceptive methods
Item
women of childbearing potential and male patients' female partners must use an acceptable method of contraception while on study, and for 3 months after study drug treatment.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0079399 (UMLS CUI [2,1])
C0682323 (UMLS CUI [2,2])
C0700589 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
pregnant or lactating women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Comorbidity Uncontrolled | Communicable Diseases | Communicable Diseases Uncontrolled | Fever | Tumour associated fever
Item
patients with uncontrolled, intercurrent illness, active or uncontrolled infections, or a fever > 38.5c (not due to tumor fever) on the day of scheduled dosing.
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C0009450 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0015967 (UMLS CUI [4])
C0948348 (UMLS CUI [5])
Illness Serious Interferes with Study Subject Participation Status | Illness Serious Interferes with research results | Medical condition Serious Interferes with Study Subject Participation Status | Medical condition Serious Interferes with research results | Laboratory Results Interfere with Study Subject Participation Status | Laboratory Results Interfere with research results
Item
patients with serious illnesses or medical conditions, including laboratory results, which, in the investigator's opinion, would interfere with a patient's participation, or with the interpretation of the results.
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C2348568 (UMLS CUI [1,4])
C0221423 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C0521102 (UMLS CUI [2,3])
C0683954 (UMLS CUI [2,4])
C3843040 (UMLS CUI [3,1])
C0205404 (UMLS CUI [3,2])
C0521102 (UMLS CUI [3,3])
C2348568 (UMLS CUI [3,4])
C3843040 (UMLS CUI [4,1])
C0205404 (UMLS CUI [4,2])
C0521102 (UMLS CUI [4,3])
C0683954 (UMLS CUI [4,4])
C1254595 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C2348568 (UMLS CUI [5,3])
C1254595 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0683954 (UMLS CUI [6,3])
Investigational New Drugs
Item
patients treated with an investigational drug within 30 days prior to study initiation.
boolean
C0013230 (UMLS CUI [1])
Hypersensitivity Histone deacetylase inhibitor | Hypersensitivity MG 0103 Component
Item
known hypersensitivity to hdac inhibitors or to any of the components of mg-0103.
boolean
C0020517 (UMLS CUI [1,1])
C1512474 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1831851 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
HIV Infection | Hepatitis B | Hepatitis C
Item
known hiv or active hepatitis b or c.
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Condition Affecting Informed Consent | Condition Affecting Protocol Compliance
Item
any condition that may affect the patient's ability to sign the icf and undergo study procedures.
boolean
C0348080 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
Condition Resulting in Patient Risk | Condition Resulting in Patient Discomfort | Protocol Compliance Consequence of
Item
any conditions that will put the patient at undue risk or discomfort as a result of adherence to study procedures.
boolean
C0348080 (UMLS CUI [1,1])
C0332294 (UMLS CUI [1,2])
C0030705 (UMLS CUI [1,3])
C0035647 (UMLS CUI [1,4])
C0348080 (UMLS CUI [2,1])
C0332294 (UMLS CUI [2,2])
C0030705 (UMLS CUI [2,3])
C2364135 (UMLS CUI [2,4])
C0525058 (UMLS CUI [3,1])
C0686907 (UMLS CUI [3,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial